Each month, the ALS Clinical Trials Unit gathers experts across academia and industry to discuss the latest issues in ALS research and drug discovery. See past presentations below:
Primary Lateral Sclerosis — Unicorn, Dragon or Other Mythological Beast?
Lauren Elman, M.D., associate professor of neurology at the Hospital of the University of Pennsylvania and Penn Medicine, discusses her research with primary lateral sclerosis (PLS), a rare motor neuron disease often mistaken for ALS.
Early Markers of Disease in Familial ALS
Katharine Nicholson, M.D., an assistant in neurology at Massachusetts General Hospital and an instructor at Harvard Medical School, discusses her work to identify key biomarkers for familial ALS..
Problems and Progress in ALS Clinical Trials
Jonathan Glass from the Emory ALS Center explains two specific issues in ALS: diagnostic delay and insensitive outcome measures. Glass provides an overview of what clinicians are now doing to combat those challenges.
ALS Preclinical Drug Discovery and Therapy Development: Finally, Real Progress!
Jeffrey Rothstein, director of the Robert Packard Center for ALS Research, covers important pathways of ALS and key differences between academic and industry drug discovery.
Challenges in Drug Development for ALS
Jinsy Andrews, director of neuromuscular clinical trials at Columbia University Irving Medical Center, discusses the unique challenges faced by researchers working to develop new medications to treat ALS.
The Expanding Landscape of Therapeutic Targets in ALS Clinical Trials
Nicholas Maragakis, director of the Johns Hopkins ALS Center for Cell Therapy and Regeneration Research, covers some of the major, clinically relevant pathways of ALS and shares examples of clinical trials that target those pathways with innovative research design.